Stock ANRO ALTO NEUROSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Alto Neuroscience, Inc.

Equities

ANRO

US02157Q1094

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-23 pm EDT 		5-day change 1st Jan Change
11.76 USD -4.23% Intraday chart for Alto Neuroscience, Inc. -8.27% 0.00%
May. 14 Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 23 Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia CI

Evolution of the average Target Price on Alto Neuroscience, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d0790.xJeXVipM3S0LQM6sQneHVJ3YBqJ70d7-RyxxaqWXOAA.ge7BJXouhF56BIeYASfGH8iuYcxW57KvCBkDJ8nAWmjxpMEbQxmOcj1xrQ~72a6f21a9eec6f850e74e318f9e9bdb5

Analyst Recommendations on Alto Neuroscience, Inc.

Stifel Initiates Alto Neuroscience With Buy Rating, Price Target is $32 MT
Baird Initiates Alto Neuroscience With Outperform Rating, Price Target is $32 MT
Jefferies Initiates Alto Neuroscience With Buy Rating, Price Target is $33 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.76 USD
Average target price
33.69 USD
Spread / Average Target
+186.48%
High Price Target
37.76 USD
Spread / Highest target
+221.09%
Low Price Target
32 USD
Spread / Lowest Target
+172.11%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alto Neuroscience, Inc.

Baird
Jefferies & Co.
Stifel Nicolaus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANRO Stock
  4. Consensus Alto Neuroscience, Inc.